Rapcabtagene Autoleucel – VJRegenMed https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Thu, 09 Mar 2023 11:31:46 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png Rapcabtagene Autoleucel – VJRegenMed https://mirror.vjregenmed.com 32 32 Phase I study of rapcabtagene autoleucel in patients with R/R DLBCL https://mirror.vjregenmed.com/video/tqvgxis7_pi-phase-i-study-of-rapcabtagene-autoleucel-in-patients-with-rr-dlbcl/ Thu, 09 Mar 2023 11:31:46 +0000 https://mirror.vjregenmed.com/video/tqvgxis7_pi-phase-i-study-of-rapcabtagene-autoleucel-in-patients-with-rr-dlbcl/ Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, gives an update on a Phase I study of rapcabtagene autoleucel in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Dr Shah explains that this next-generation CD19 CAR-T therapy has been manufactured using T-Charge™, which allows this product to be manufactured faster than other CAR-T therapies, thus helping it to preserve T cell stemness, decrease the dose of infused CAR-Ts, and increase its overall quality. The study identified a safe dose level for further investigations and reported low rates of cytokine release syndrome (CRS). This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

]]>